Davita Inc (NYSE:DVA) – Investment analysts at William Blair lifted their Q2 2020 earnings estimates for shares of Davita in a report issued on Tuesday, February 11th. William Blair analyst M. Larew now expects that the company will post earnings per share of $1.58 for the quarter, up from their prior forecast of $1.39. William Blair also issued estimates for Davita’s Q1 2021 earnings at $1.54 EPS, Q2 2021 earnings at $1.67 EPS, Q3 2021 earnings at $1.57 EPS, Q4 2021 earnings at $1.75 EPS and FY2021 earnings at $6.53 EPS.
Davita (NYSE:DVA) last posted its earnings results on Monday, February 10th. The company reported $1.86 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $1.66 by $0.20. The company had revenue of $2.90 billion during the quarter, compared to the consensus estimate of $2.92 billion. Davita had a net margin of 7.12% and a return on equity of 22.93%. The company’s revenue for the quarter was up 2.7% compared to the same quarter last year. During the same period in the previous year, the firm posted $0.90 earnings per share.
Several other analysts also recently commented on DVA. SunTrust Banks set a $90.00 target price on shares of Davita in a research report on Tuesday. Zacks Investment Research raised shares of Davita from a “hold” rating to a “strong-buy” rating and set a $93.00 target price for the company in a research report on Wednesday. Goldman Sachs Group raised shares of Davita from a “neutral” rating to a “buy” rating in a research report on Friday, January 24th. Wolfe Research downgraded shares of Davita from an “outperform” rating to a “market perform” rating and set a $57.00 target price for the company. in a research report on Friday, October 25th. Finally, Deutsche Bank began coverage on shares of Davita in a research report on Friday, January 3rd. They issued a “buy” rating and a $60.00 target price for the company. One equities research analyst has rated the stock with a sell rating, eight have given a hold rating, two have issued a buy rating and one has issued a strong buy rating to the company. Davita currently has an average rating of “Hold” and a consensus target price of $71.43.
DVA stock opened at $85.98 on Thursday. The company has a quick ratio of 1.77, a current ratio of 1.81 and a debt-to-equity ratio of 4.26. The company has a market capitalization of $11.00 billion, a price-to-earnings ratio of 16.01, a P/E/G ratio of 0.63 and a beta of 1.70. Davita has a 12 month low of $43.40 and a 12 month high of $90.15. The firm has a 50 day moving average of $79.34 and a two-hundred day moving average of $66.99.
Several institutional investors have recently modified their holdings of DVA. Amundi Pioneer Asset Management Inc. grew its stake in shares of Davita by 31.9% during the first quarter. Amundi Pioneer Asset Management Inc. now owns 154,693 shares of the company’s stock worth $8,398,000 after purchasing an additional 37,375 shares in the last quarter. Ladenburg Thalmann Financial Services Inc. boosted its stake in Davita by 16.9% in the second quarter. Ladenburg Thalmann Financial Services Inc. now owns 5,131 shares of the company’s stock valued at $289,000 after acquiring an additional 741 shares in the last quarter. NuWave Investment Management LLC boosted its stake in Davita by 1,166.3% in the third quarter. NuWave Investment Management LLC now owns 1,013 shares of the company’s stock valued at $57,000 after acquiring an additional 933 shares in the last quarter. Nisa Investment Advisors LLC boosted its stake in Davita by 64.7% in the third quarter. Nisa Investment Advisors LLC now owns 24,240 shares of the company’s stock valued at $1,383,000 after acquiring an additional 9,520 shares in the last quarter. Finally, Robeco Institutional Asset Management B.V. boosted its stake in Davita by 1,907.2% in the third quarter. Robeco Institutional Asset Management B.V. now owns 78,018 shares of the company’s stock valued at $4,451,000 after acquiring an additional 74,131 shares in the last quarter. Institutional investors and hedge funds own 95.40% of the company’s stock.
DaVita Inc provides kidney dialysis services for patients suffering from chronic kidney failure or end stage renal disease (ESRD). The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. It also provides outpatient, hospital inpatient, and home-based hemodialysis services; owns clinical laboratories that provide routine laboratory tests for dialysis and other physician-prescribed laboratory tests for ESRD patients; and management and administrative services to outpatient dialysis centers.
Receive News & Ratings for Davita Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Davita and related companies with MarketBeat.com's FREE daily email newsletter.